⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARWR News
Arrowhead Research Corporation
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
businesswire.com
ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
businesswire.com
ARWR
Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines Expand
globenewswire.com
A
BC
IONS
ALNY
ARWR
TMO
AMGN
DHR
LRCX
MRK
MLSS
IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight
globenewswire.com
NVS
VRTX
BIIB
VTRS
AZN
IONS
TAK
ARWR
BHVN
NVO
LLY
LXRX
XRTX
REGN
FMS
MDT
AMPH
DRCT
BMRC
MAZE
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
businesswire.com
ARWR
Form 8-K
sec.gov
ARWR
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight
globenewswire.com
AZN
NVS
ABBV
BMY
GILD
REGN
VRTX
BIIB
JNJ
MRK
ARWR
TAK
VERA
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight
globenewswire.com
IMVT
ROIV
MRK
NVS
REGN
UCB
JNJ
ARGX
AMGN
VIR
IPHA
ARWR
APLS
CABA
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
businesswire.com
ARWR
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
businesswire.com
ARWR